|
|
|
|
Novo Nordisk Receives Marketing Authorisation For Victoza
Victoza, once-daily human Glucagon-Like Peptide-1 analogue, developed for the treatment of type 2 diabetes Related News Stolen insulin lot numbers are: XZF0036, XZF0037, XZF0038 ...Liraglutide to treat type 2 diabetes ... Novo...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
Novo Nordisk's Victoza(R) (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza(R) for the treatment of type 2 diabetes in adults.
|
|
|
Novo Nordisk A/S -- Regulatory Approval
Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The authorisation covers all 27 European Union member states. Victoza is the brand...
|
|
|
::: Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe
Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The authorisation covers all 27 European Union member states. Victoza is the brand...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
(MARKETWIRE via COMTEX) -- Novo Nordisk's Victoza(R) (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza(R) for the treatment of...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
Novo Nordisk's Victoza(R) (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza(R) for the treatment of type 2 diabetes in adults.
|
|
|
Novo Nordisk A/S -- Regulatory Approval
(MARKETWIRE via COMTEX) -- NVO | Quote | Chart | News | PowerRating -- Novo Nordisk's Victoza(R) (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
(MARKETWIRE via COMTEX News Network) -- Novo Nordisk's Victoza(R) (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza(R) for the...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The...
|
|
|
Novo Nordisk's Victoza Gets Marketing Authorisation In Europe -Quick Facts
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Novo Nordisk (NVO: News , NONOF.PK) announced that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The authorisation...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
BAGSVAERD, DENMARK, Jul 03 (MARKET WIRE) -- Novo Nordisk's Victoza(R) (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza(R) for...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
BAGSVAERD, DENMARK, Jul 03 (MARKET WIRE) -- Novo Nordisk's Victoza(R) (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza(R) for...
|
|
|
Regulatory Approval
Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
BAGSVAERD, DENMARK -- (Marketwire) -- 07/03/09 -- Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The...
|
|
|
Novo Nordisk A/S -- Regulatory Approval
- Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.The...
|
|
|
Novo Nordisk A/S: Novo Nordisk A/S -- Regulatory Approval
SOURCE: Novo Nordisk A/S BAGSVAERD, DENMARK--(Marketwire - July 3, 2009) - Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe Novo Nordisk announced today that the European Commission has granted marketing...
|
|
|
Lead 6:
Editors' note: Liraglutide, a once-daily glucagon-like peptide-1 receptor agonist, has previously been shown to be effective at reducing glycosylated haemoglobin in patients with type 2 diabetes.The LEAD-6 trial compares liraglutide...
|
|
|
Takeda seeks additional indication of alogliptin for combo therapy with thiazolidinediones
Takeda Pharmaceutical Company Limited (Takeda) announced that it submitted an application for an additional indication of alogliptin (generic name, development code: SYR-322) for combination therapy with thiazolidinediones, and a new drug...
|
|
|
Takeda files for an additional indication of Alogliptin
Japanese company, Takeda Pharmaceutical has submitted an application for an additional indication of alogliptin (generic name, development code: SYR-322) for combination therapy with thiazolidinediones, and a new drug application (NDA) of...
|
|
|
Takeda Submitted an Application for an Additional Indication of Alogliptin for Combination Therapy with Thiazo
Takeda Pharmaceutical Company Limited (Takeda) today announced that it submitted an application for an additional indication of alogliptin (generic name, development code: SYR-322) for combination therapy with thiazolidinediones, and a new...
|
|
|
Diabetes - Research on diabetes described by scientists at University of Ulster
We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. 'Enzyme-resistant glucagon-like peptide-1 (GLP-1) receptor agonists and GIP receptor antagonists have been proposed to have...
|
|
|
ONGLYZA„ (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
(NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that their marketing authorization application for ONGLYZA„ (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the...
|
